Primary cutaneous aggressive epidermotropic cytotoxic CD8⁺ T‐cell lymphoma: long‐term remission after brentuximab vedotin

Rapidly progressive hyperpigmented keratotic plaques with epidermotropism

“…4 A recent report has highlighted longterm remission with brentuximab vedotin monotherapy. 9 In the absence of a standard accepted treatment for this lymphoma and skin-limited disease in our patient, we tried methotrexate initially, but later escalated to monoagent chemotherapies such as doxorubicin and gemcitabine due to inadequate response.…”

Long-Term Remission After Matched Sibling Donor Hematopoietic Cell Transplantation in a Patient With Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma

“…To the best of our knowledge, our patient had the longest CR of 96 months (as of April 2021) reported in the literature. The second-longest CR reported in the literature was 58 months on brentuximab monotherapy [ 7 ]. We believe four main reasons contributed to the success in this case.…”

Rapidly Evolving Necrotic Plaques and Nodules in a Middle-aged Woman

“…Therapeutic management consists of multiagent chemotherapy and immunotherapy regimens, in addition to consideration of hematopoietic stem-cell transplant and total skin electron-beam therapy . Prognosis is poor, and few studies report a successful, durable response to therapy . Median survival time is estimated to be 12 to 32 months from the time of diagnosis .…”

“…[2][3][4] Prognosis is poor, and few studies report a successful, durable response to therapy. 4,7 Median survival time is estimated to be 12 to 32 months from the time of diagnosis. 1,3 The present case reveals a clinicopathologic correlation between the rapidly evolving ulcerating tumors noted in this patient and markedly epidermotropic, atypical cytotoxic lymphocytes positive for CD3, CD8, TIA1, granzymes, and Bf1 and negative for CD4, CD30, CD56, and Epstein-Barr virus-encoded RNA.…”